Solos Endoscopy Inc. (OTC:SNDY) trademarked the name of its MammoView breast endoscopy system.
The Boston-based company’s device uses tiny endoscopes to provide images from within the milk ducts of the breast, where many cancers begin.
The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Wall Street Beat | Earnings Reports | Funding Roundup | Mergers & Acquisitions | Initial Public Offerings | Legal News
Solos Endoscopy Inc. (OTC:SNDY) trademarked the name of its MammoView breast endoscopy system.
The Boston-based company’s device uses tiny endoscopes to provide images from within the milk ducts of the breast, where many cancers begin.
Medtronic Inc. (NYSE:MDT) is asking the Food & Drug Administration to approve its Activa deep-brain stimulation device for the treatment of epilepsy, after an FDA panel narrowly recommended the expanded indication be approved.
The Fridley, Minn.-based medical devices giant said the journal Epilepsia published results from its Santé clinical trial of the device, which examined its efficacy in reducing seizures by sending a trickle of electricity to the anterior nuclei of the thalamus.
Haemonetics Corp. (NYSE:HAE) extended its offer for GlobalMed Technologies Inc. to give the California-based software provider time to settle a shareholders lawsuit filed to block the acquisition.
Braintree, Mass.-based Haemonetics issued a $1.22-per-share offer, worth about $60 million and set to expire tonight at midnight, for GlobalMed Feb. 1.
Rhythmia Medical Inc. raised nearly $2.7 million in a third-round equity sale to a group of 14 investors, according to new securities documents.
Burlington, Mass.-based Rhythmia, founded in 2004 by two Israeli entrepreneurs, is developing medical devices able to quickly map the electrical activity of the heart and pinpoint catheter ablation procedures.
Anika Therapeutics Inc. (NSDQ:ANIK) saw fourth-quarter profits plunge 36.3 percent as it paid for an acquisition and the relocation of some of its manufacturing operations to its Bedford, Mass., headquarters.
Anika, which makes cosmetic and tissue-repair products using hyaluronic acid technology, posted net income of $697,000 (or 6 cents per diluted share) on revenues of $10.6 million during the three months ended Dec. 31, 2009. That compares with net income of $1.1 million, or 10 cents per diluted share, on revenues of $9 million during Q4 2008.
Covidien (NYSE:COV) is looking to repurchase about $1 billion worth of its own company stock and plans to kick out its usual 18-cent quarterly dividend to shareholders.
The Mansfield, Mass.-based medical equipment monolith said it will purchase up to $1 billion of its own stock, based on market conditions. Covidien added that it will institute a program to offset any dilution that could come from equity compensation plans.
Medtronic Inc. (NYSE:MDT) won a supplemental PMA from the Food & Drug Administration for the latest version of its MiniMed Paradigm REAL-Time diabetes management system, which it touts as the “industry’s only integrated diabetes management system.”
And the Fridley, Minn.-based medical devices monolith put another product into the PMA pipeline, its Arctic Front cryoablation catheter system, after revealing positive study results at a recent conference.
Top executives at Cambridge Heart Inc. (NSDQ:CAMH) agreed to 10 percent paycuts this year and will give up cash bonuses for 2009 as the money-poor manufacturer works to commercialize its cardiac monitoring tools.
The Tewksbury, Mass.-based company also eliminated per-meeting cash payments received by the three non-employee members on its board of directors and halved the $140,000 consulting fee it pays to its scientific founder. The reductions, approved March 11, should result in savings of at least $300,000 during 2010, with about a third of the extra funds resulting from the cuts in board compensation.
A Food & Drug Administration panel said the risks of implanting cardiac resynchronization therapy defibrillators into patients suffering from milder forms of heart failure may not be worth the benefit on the open marketplace, even though Boston Scientific Corp. (NYSE:BSX) provided sound evidence of the devices’ effectiveness in its Madit-CRT study last fall.
In materials released ahead of its March 18 meeting, the regulatory agency said that the Natick, Mass.-based medical device giant met the basic goals of the massive 1,800-plus patient study by proving that the company’s therapy was effective in reducing heart failure events.
By Mary Vanac
Mentor, Ohio-based Steris Corp. (NYSE:STE) launched a system that integrates operating room visualization technologies on a single touch-screen.
Introduced at the Assn. of periOperative Registered Nurses Congress in Denver, the Harmony iQ 2100 Integration System is a joint venture produced in tandem with VTS Medical Systems LLC of Melville, N.Y. It takes several units that control cameras, imaging devices and navigation equipment off a stacked tower or rack and consolidates them on one computer screen and microprocessor.
Abiomed Inc. (NSDQ:ABMD) was hit with a Class I recall of its AB5000 Circulatory Support System after receiving reports that the computer supplying power to the company’s disposable heart pumps may shut down without warning.
Class 1 recalls are the most serious type of recall and involve situations in which there is a reasonable probability that use of these products could cause serious injury or death.